Improvement of muscle regeneration function in athletes Musculoskeletal Diseases
Conditions
Interventions
Current interventions as of 04/07/2023:
The experiment was conducted according to a randomized crossover design in which each subject participated in a DN familiarization intervention 14 days prior to
Fernández-de-las-Peñas & Dommerholt, 2018). If there was no response, further insertions were not continued. The e
Sponsors
Provita Medical Center
Eligibility
Sex/Gender
Male
Age
18 Years to 40 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18-40 years 2. Minimum of 3 years of training experience 3. Documented record (data of professional fights on tapology.com, amateur fights on mmapolska.org) of amateur or professional fights, at least three 4. Training at least four times a week 5. Participants in the study had to be abstinent from training for 48 hours and abstain from training for 24 hours during the study 6. Due to PU measurements, they were asked to refrain from consuming ergogenic drinks for 4 hours before the test
Exclusion criteria
Exclusion criteria: 1. Elevated blood pressure before the test (blood pressure >140/90 mmHg) 2. People with musculoskeletal system injuries, damage or unspecified skin and myofascial lesions 3. Participants were also not allowed to have a tattoo at the measurement site because it interfered with tissue perfusion measurements 4. Needle phobia 5. Extreme fatigue 6. Fever 7. Infection 8. Allergy to nickel 9. Exclusion could occur at any time during the study at the participant's request
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Current primary outcome measures as of 04/07/2023: 1. Muscle tone (T = Hz), stiffness (S = N/m), and elasticity (E= NaN ), measured with a myotonometer (MyotonPRO AS, Myoton Ltd, Estonia 2021) at rest, 5 minutes, 24 hours after DN therapy 2. Muscle pain threshold (P PT= kG or N) measured with the FDIX algesimeter (Wagner Instruments, Greenwich, CT, USA 2013) at rest, 5 minutes, 24 hours after DN therapy 3. Perfusion unit (PU) index measured using laser Doppler flowmetry (LDF) (Perimed, Sweden 2004) at rest, 5 minutes and 24 hours after DN therapy 4. Muscle power (relative strength index [RSI]) measured using ForceDecks measuring platform (Vald Performance Australia 2012) at rest, 5 minutes and 24 hours after DN therapy 5. Maximum isometric force measured by electronic dynamometer 106 China 2022 at rest, 5 minutes and 24 hours after DN therapy All measurements measured between 10-12 AM Previous primary outcome measures: 1. Muscle tone (T = Hz), stiffness (S = N/m), and elasticity (E= NaN ), measured with a myotonometer (MyotonPRO AS, Myoton Ltd, Estonia 2021) at rest, 5 minutes, 24 hours after DN therapy 2. Muscle pain threshold (P PT= kG or N) measured with the FDIX algesimeter (Wagner Instruments, Greenwich, CT, USA 2013) at rest, 5 minutes, 24 hours after DN therapy 3. Perfusion unit (PU) index measured using laser Doppler flowmetry (LDF) (Perimed, Sweden 2004) at rest, 5 minutes and 24 hours after DN therapy 4. Muscle power (relative strength index [RSI]) measured using ForceDecks measuring platform (Vald Performance Australia 2012) at rest, 5 minutes and 24 hours after DN therapy All measurements measured between 10-12 AM | — |
Secondary
| Measure | Time frame |
|---|---|
| There are no secondary outcome measures | — |
Countries
Poland
Outcome results
None listed